0000899243-23-002075.txt : 20230118 0000899243-23-002075.hdr.sgml : 20230118 20230118175822 ACCESSION NUMBER: 0000899243-23-002075 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230113 FILED AS OF DATE: 20230118 DATE AS OF CHANGE: 20230118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Katz Barrett CENTRAL INDEX KEY: 0001841628 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36483 FILM NUMBER: 23535406 MAIL ADDRESS: STREET 1: 6200 LOOKOUT ROAD STREET 2: C/O MIRAGEN THERAPEUTICS, INC. CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viridian Therapeutics, Inc.\DE CENTRAL INDEX KEY: 0001590750 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 471187261 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 617.272.4600 MAIL ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: SIGNAL GENETICS, INC. DATE OF NAME CHANGE: 20140710 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-13 0 0001590750 Viridian Therapeutics, Inc.\DE VRDN 0001841628 Katz Barrett C/O VIRIDIAN THERAPEUTICS, INC. 221 CRESCENT STREET, SUITE 401 WALTHAM MA 02453 0 1 0 0 Chief Medical Officer Common Stock 2023-01-13 4 M 0 4147 23.03 A 4147 D Common Stock 2023-01-13 4 S 0 4147 37.01 D 0 D Common Stock 2023-01-17 4 M 0 24853 23.03 A 24853 D Common Stock 2023-01-17 4 S 0 24853 37.21 D 0 D Stock Option (Right to Buy) 23.03 2023-01-13 4 M 0 4147 0.00 D 2031-01-17 Common Stock 4147 291853 D Stock Option (Right to Buy) 23.03 2023-01-17 4 M 0 24853 0.00 D 2031-01-17 Common Stock 24853 267000 D This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.05. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.58. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. /s/ Lara Meisner, Attorney-in-Fact for Barrett Katz 2023-01-18